PMID- 20421783
OWN - NLM
STAT- MEDLINE
DCOM- 20100615
LR  - 20151119
IS  - 1532-0979 (Electronic)
IS  - 0147-5185 (Linking)
VI  - 34
IP  - 6
DP  - 2010 Jun
TI  - Silver in situ hybridization (SISH) for determination of HER2 gene status in 
      breast carcinoma: comparison with FISH and assessment of interobserver 
      reproducibility.
PG  - 767-76
LID - 10.1097/PAS.0b013e3181d96231 [doi]
AB  - The importance of HER2 status in breast cancer management has focused attention 
      on the ability of clinical assays to correctly assign HER2 amplification status. 
      There is no consensus as to the best method for assessing HER2 status. 
      Disadvantages of fluorescence in situ hybridization (FISH) testing include longer 
      time required for staining and scoring slides, requirements for specialized 
      training and fluorescence microscopy, and loss of the signal due to quenching of 
      the fluorescent dye. Silver-enhanced in situ hybridization (SISH) is a rapid 
      fully automated assay providing permanently stained slides that are interpreted 
      by conventional bright field microscopy which enables pathologists to evaluate 
      slides within the context of tissue morphology. This study evaluates the 
      concordance between SISH and FISH assays in determining the status of HER2 gene 
      amplification in a cohort of 298 primary invasive breast carcinomas. Furthermore, 
      we assessed in detail the variables contributing to interobserver interpretive 
      reproducibility of HER2 SISH among 10 pathologists. HER2 was quantified using the 
      ratio of HER2 to CHR17 signals using the conventional historical interpretation 
      scale and also by the American Society of Clinical Oncology/College of American 
      Pathologists reporting scheme. For SISH status determined by consensus among 10 
      pathologists, overall concordance between SISH and FISH was identified in 288 of 
      298 cases (96.6%) using the conventional Food and Drug Administration approved 
      criteria. Overall agreement was observed in 282 of 285 cases (98.9%) using the 
      American Society of Clinical Oncology/College of American Pathologists result 
      reporting scheme (with equivocal cases removed). In conclusion, SISH represents a 
      novel approach for the determination of HER2 status in breast cancer. The overall 
      concordance between SISH and FISH is excellent, and the interpretation of SISH 
      results by pathologists is most reproducible using the HER2/CHR17 ratio.
FAU - Papouchado, Bettina G
AU  - Papouchado BG
AD  - Pathology and Laboratory Medicine Institute, Lerner College of Medicine, 
      Cleveland Clinic, Cleveland, OH 44195, USA. papoucb@ccf.org
FAU - Myles, Jonathan
AU  - Myles J
FAU - Lloyd, Ricardo V
AU  - Lloyd RV
FAU - Stoler, Mark
AU  - Stoler M
FAU - Oliveira, Andre M
AU  - Oliveira AM
FAU - Downs-Kelly, Erinn
AU  - Downs-Kelly E
FAU - Morey, Adrienne
AU  - Morey A
FAU - Bilous, Michael
AU  - Bilous M
FAU - Nagle, Ray
AU  - Nagle R
FAU - Prescott, Nichole
AU  - Prescott N
FAU - Wang, Lin
AU  - Wang L
FAU - Dragovich, Lidija
AU  - Dragovich L
FAU - McElhinny, Abigail
AU  - McElhinny A
FAU - Garcia, Carole Ferrell
AU  - Garcia CF
FAU - Ranger-Moore, Jim
AU  - Ranger-Moore J
FAU - Free, Heather
AU  - Free H
FAU - Powell, William
AU  - Powell W
FAU - Loftus, Margaret
AU  - Loftus M
FAU - Pettay, James
AU  - Pettay J
FAU - Gaire, Fabien
AU  - Gaire F
FAU - Roberts, Christopher
AU  - Roberts C
FAU - Dietel, Manfred
AU  - Dietel M
FAU - Roche, Patrick
AU  - Roche P
FAU - Grogan, Thomas
AU  - Grogan T
FAU - Tubbs, Raymond
AU  - Tubbs R
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Am J Surg Pathol
JT  - The American journal of surgical pathology
JID - 7707904
RN  - 0 (Silver Compounds)
SB  - IM
MH  - Breast Neoplasms/*genetics
MH  - Female
MH  - *Genes, erbB-2
MH  - Humans
MH  - In Situ Hybridization/*methods
MH  - In Situ Hybridization, Fluorescence
MH  - Nucleic Acid Amplification Techniques/*methods
MH  - Observer Variation
MH  - Reproducibility of Results
MH  - *Silver Compounds
EDAT- 2010/04/28 06:00
MHDA- 2010/06/16 06:00
CRDT- 2010/04/28 06:00
PHST- 2010/04/28 06:00 [entrez]
PHST- 2010/04/28 06:00 [pubmed]
PHST- 2010/06/16 06:00 [medline]
AID - 10.1097/PAS.0b013e3181d96231 [doi]
PST - ppublish
SO  - Am J Surg Pathol. 2010 Jun;34(6):767-76. doi: 10.1097/PAS.0b013e3181d96231.